Navigation Links
Medarex to Present at the Needham Cancer Therapeutics Conference
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that it is scheduled to present at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference at 11:20 a.m. Eastern Time on Thursday, March 26, 2009. The event will be webcast live and will be available in the Investor Relations section of the Medarex website at www.medarex.com. An archived edition of the presentation will be available following the event.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. Over forty of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with the most advanced product candidates currently in Phase 3 clinical trials, the subject of regulatory applications for marketing authorization or approved in Canada and Europe. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
2. Medarex Announces Allowance of Investigational New Drug Application for Companys First Antibody-Drug Conjugate, MDX-1203
3. Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Medarex to Present at the RBC Capital Markets Healthcare Conference
5. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
6. Medarex Announces 2008 Third Quarter Financial Results
7. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
8. Medarex to Present at the UBS Global Life Sciences Conference
9. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
10. BioWa and Medarex Announce License of BioWas COMPLEGENT(TM) Technology
11. Medarex Announces July 10 Live Webcast of R&D Day Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... WOODLANDS, Texas , May 3, 2016  Dr. ... certified plastic surgeon in The Woodlands, Texas ... that destroys 24 percent of treated fat cells in ... and woman. Close to 90 percent of Americans report ... treatment options. Nonsurgical fat reduction procedures are a growing ...
(Date:5/2/2016)... ... ... StarNet Communications Corp, ( http://www.starnet.com/ ) a leading publisher of remote Linux ... to its flagship X-Win32 PC X server. The new modules enable X-Win32 to ... over encrypted SSH. , Traditionally, users of PC X servers deploy the XDMCP protocol ...
(Date:4/29/2016)... 2016 According to a ... "Separation Systems for Commercial Biotechnology Market - Global ... 2015 - 2023", the separation systems for commercial ... in 2014 and is projected to expand at ... to reach US$ 19,227.8 Mn in 2023. ...
(Date:4/28/2016)... PUNE, India , April 28, 2016 ... PT, JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, ... Application, and Geography - Global Forecast to 2022", published ... to USD 2.94 Billion by 2022, at a CAGR ... Browse 70 market data Tables and 94 Figures spread ...
Breaking Biology Technology:
(Date:3/3/2016)... Calif. , March 3, 2016  FlexTech, a ... the categories of Innovation, Research & Development, Leadership in ... Leadership. This is the 9 th year of ... group of companies and individuals from past years ... based on a pre-described set of criteria, by a ...
(Date:3/3/2016)... SOTO, Kansas , March 3, 2016 ... Oncimmune,s Early CDT®-Lung, a blood test to aid ... cancer Early CDT®-Lung test to its clients ... Early CDT®-Lung test to its clients which include ... a leader in early cancer detection, today announced a ...
(Date:3/2/2016)... , March 2, 2016 ... of the "Global Biometrics as a ... offering. --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ... "Global Biometrics as a Service Market 2016-2020" ... --> Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ...
Breaking Biology News(10 mins):